Latest News
Cure SMA Launches Phase 11 SMA Industry Collaboration
Cure SMA is pleased to announce the launch of Phase 11 initiates for the SMA Industry Collaboration. The SMA Industry Collaboration is a multi-faceted partnership that brings together pharmaceutical companies, […]
Scholar Rock Resubmits Biologics License Application (BLA) for Apitegromab to the FDA
Today, Scholar Rock announced that it has resubmitted its Biologics License Application (BLA) to the Food and Drug Administration (FDA) for apitegromab, an investigational therapy for the treatment of people […]
Biogen Receives FDA Approval of High Dose SPINRAZA for the Treatment of SMA
Biogen today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the High Dose regimen of SPINRAZA (nusinersen) to treat people living with spinal […]
Cure SMA Awards $150,000 Grant to Tetsuya Akiyama, MD, PhD, Stanford University School of Medicine
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our […]
Cure SMA Expands Travel Support Package Eligibility to Include Teens with SMA
Cure SMA is excited to share an important update to our travel support programs. In response to community feedback and the growing need for accessible travel support for younger individuals, […]
Genentech Issues Community Letter Regarding Emugrobart
Today, Genentech announced the discontinuation of emugrobart (an investigational anti-myostatin antibody, also known as GYM329) into Phase III development for spinal muscular atrophy (SMA). The decision to stop clinical development […]